Justin Ritz

777 total citations
16 papers, 138 citations indexed

About

Justin Ritz is a scholar working on Infectious Diseases, Virology and Neurology. According to data from OpenAlex, Justin Ritz has authored 16 papers receiving a total of 138 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 6 papers in Virology and 5 papers in Neurology. Recurrent topics in Justin Ritz's work include HIV/AIDS Research and Interventions (7 papers), HIV Research and Treatment (6 papers) and HIV/AIDS drug development and treatment (6 papers). Justin Ritz is often cited by papers focused on HIV/AIDS Research and Interventions (7 papers), HIV Research and Treatment (6 papers) and HIV/AIDS drug development and treatment (6 papers). Justin Ritz collaborates with scholars based in United States, Brazil and South Africa. Justin Ritz's co-authors include Karen H. Antman, Robert W. Finberg, Kathleen Kehoe, Michael A. Lew, Lee M. Nadler, Evelyn Hogg, Michael D. Hughes, Ann C. Collier, Joseph J. Eron and Robert Gross and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

Justin Ritz

11 papers receiving 135 citations

Peers

Countries citing papers authored by Justin Ritz

Since Specialization

Citations

This map shows the geographic impact of Justin Ritz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin Ritz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin Ritz more than expected).

Fields of papers citing papers by Justin Ritz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin Ritz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin Ritz. The network helps show where Justin Ritz may publish in the future.

Co-authorship network of co-authors of Justin Ritz

This figure shows the co-authorship network connecting the top 25 collaborators of Justin Ritz. A scholar is included among the top collaborators of Justin Ritz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin Ritz. Justin Ritz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial 2025 ·Contemporary Clinical Trials ·Mark J Giganti, Kara W Chew, Carlee Moser, (unknown), (unknown), Jonathan Z. Li, Justin Ritz, Arzhang Cyrus Javan, David A. Wohl, Eric S. Daar, Judith S. Currier, Davey M. Smith, Michael D. Hughes	0
2	Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies 2025 ·iScience ·Rachel Bender Ignacio, Kara W Chew, Carlee Moser, Judith S. Currier, (unknown), Arzhang Cyrus Javan, Mark J Giganti, Justin Ritz, M.R.J. Gibbs, (unknown), (unknown), Eric S. Daar, Manish C. Choudhary, (unknown), Courtney V. Fletcher, Jonathan Z. Li, Michael D. Hughes, Davey M. Smith, David A. Wohl	0
3	Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials 2024 ·SHILAP Revista de lepidopterología ·(unknown), Justin Ritz, Michael D. Hughes, Mitch Matoga, Mina C. Hosseinipour	1
4	SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19 2024 ·Clinical Infectious Diseases ·Nikolaus Jilg, Mark J Giganti, Kara W Chew, Kathryn Shaw‐Saliba, Justin Ritz, Carlee Moser, Teresa H. Evering, Eric S. Daar, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, (unknown), Robin Dewar, Davey M. Smith, Jonathan Z. Li	0
5	Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial 2024 ·EClinicalMedicine ·Teresa H. Evering, Carlee Moser, Nikolaus Jilg, Justin Ritz, David A. Wohl, Jonathan Z. Li, David M. Margolis, Arzhang Cyrus Javan, Joseph J. Eron, Judith S. Currier, Eric S. Daar, Davey M. Smith, Michael D. Hughes, Kara W Chew, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
6	Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial 2023 ·The Journal of Infectious Diseases ·Kara W Chew, Carlee Moser, (unknown), David A. Wohl, Eric S. Daar, Justin Ritz, Arzhang Cyrus Javan, Joseph J. Eron, Judith S. Currier, Davey M. Smith, Michael D. Hughes, (unknown)	2
7	Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses 2022 ·JCI Insight ·Sydney I. Ramirez, Alba Grifoni, Daniela Weiskopf, Urvi M. Parikh, Amy Heaps, Farhoud Faraji, Scott F. Sieg, Justin Ritz, Carlee Moser, Joseph J. Eron, Judith S. Currier, Paul Klekotka, Alessandro Sette, David A. Wohl, Eric S. Daar, Michael D. Hughes, Kara W Chew, Davey M. Smith, Shane Crotty	5
8	1063. Female sex and SARS-CoV-2 Serostatus Predict Nasopharyngeal RNA Clearance during Early COVID-19 2022 ·Open Forum Infectious Diseases ·Carlee Moser, Jonathan Z. Li, Joseph J. Eron, Evgenia Aga, Eric S. Daar, David A. Wohl, (unknown), Arzhang Cyrus Javan, Rachel Bender Ignacio, Prasanna Jagannathan, Justin Ritz, Scott F. Sieg, Urvi M. Parikh, Michael D. Hughes, Judith S. Currier, Davey M. Smith, Kara W Chew	0
9	Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019 2022 ·Clinical Infectious Diseases ·Yijia Li, Linda J Harrison, Kara W Chew, (unknown), David A. Wohl, Eric S. Daar, Teresa H. Evering, (unknown), Mark J Giganti, Justin Ritz, Arzhang Cyrus Javan, Robert W. Coombs, Carlee Moser, Michael D. Hughes, Joseph J. Eron, Davey M. Smith, Jonathan Z. Li	5
10	Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy 2020 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Catherine Godfrey, Michael D. Hughes, Justin Ritz, Lara E. Coelho, Robert Gross, Robert A. Salata, Rosie Mngqibisa, Carole L. Wallis, (unknown), Mitch Matoga, Selvamuthu Poongulali, Marije Van Schalkwyk, Evelyn Hogg, Courtney V. Fletcher, Beatriz Grinsztejn, Ann C. Collier, (unknown)	5
11	HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial 2020 ·UNC Libraries ·Sally Hodder, Carl J. Fichtenbaum, Karen T. Tashima, Joseph J. Eron, Richard Haubrich, Karin L. Klingman, Justin Ritz, Jorge Luis Santana, Rajesh T. Gandhi, Timothy Wilkin, Victoria A. Johnson, Laura Smeaton, Adriana Andrade	0
12	Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial 2019 ·The Lancet Digital Health ·Robert Gross, Justin Ritz, Michael D. Hughes, Robert A. Salata, Peter Mugyenyi, Evelyn Hogg, (unknown), Catherine Godfrey, Carole L. Wallis, John W. Mellors, Victor Mudhune, Sharlaa Badal‐Faesen, Beatriz Grinsztejn, Ann C. Collier	23
13	Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS) 2019 ·The Journal of Infectious Diseases ·Rajesh T. Gandhi, Karen T. Tashima, Laura Smeaton, (unknown), Justin Ritz, Adriana Andrade, Joseph J. Eron, Evelyn Hogg, Carl J. Fichtenbaum	11
14	Diverse Human Immunodeficiency Virus–1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings 2019 ·Clinical Infectious Diseases ·Carole L. Wallis, Michael D. Hughes, Justin Ritz, Raquel Viana, (unknown), Shanmugam Saravanan, Marije Van Schalkwyk, Rosie Mngqibisa, Robert A. Salata, Peter Mugyenyi, Evelyn Hogg, (unknown), (unknown), Robert Gross, Catherine Godfrey, Ann C. Collier, Beatriz Grinsztejn, John W. Mellors	2
15	HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors 2015 ·Annals of Internal Medicine ·Karen T. Tashima, Laura Smeaton, Carl J. Fichtenbaum, Adriana Andrade, Joseph J. Eron, Rajesh T. Gandhi, Victoria A. Johnson, Karin L. Klingman, Justin Ritz, Sally Hodder, Jorge Santana, Timothy Wilkin, Richard Haubrich, (unknown)	11
16	Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. 1995 ·Journal of Clinical Oncology ·Michael A. Lew, Kathleen Kehoe, Justin Ritz, Karen H. Antman, Lee M. Nadler, (unknown), Robert W. Finberg	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact